BCLI Receives $3.1 Million from Warrant Exercises
Jan 7, 2015 13:46:44 GMT
RLC, selluwud, and 1 more like this
Post by JHam on Jan 7, 2015 13:46:44 GMT
BrainStorm Announces Receipt of Approximately $3.1 Million from Warrant Exercises
NEW YORK and PETACH TIKVAH, Israel, Jan. 7, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that since January 2, 2015 it has received approximately $3.1 million from the exercise of warrants for approximately 700 thousand shares, which were issued in a June 2012 private placement.
BrainStorm Cell Therapeutics
"We are pleased that investors in the 2012 financing have been able to exercise these warrants, which will expire later this month," stated Tony Fiorino, MD, PhD, BrainStorm's CEO. "The cash further bolsters our balance sheet and will support our clinical and preclinical research efforts, including the planned multi-dose study of NurOwn™ in amyotrophic lateral sclerosis."
NEW YORK and PETACH TIKVAH, Israel, Jan. 7, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that since January 2, 2015 it has received approximately $3.1 million from the exercise of warrants for approximately 700 thousand shares, which were issued in a June 2012 private placement.
BrainStorm Cell Therapeutics
"We are pleased that investors in the 2012 financing have been able to exercise these warrants, which will expire later this month," stated Tony Fiorino, MD, PhD, BrainStorm's CEO. "The cash further bolsters our balance sheet and will support our clinical and preclinical research efforts, including the planned multi-dose study of NurOwn™ in amyotrophic lateral sclerosis."
